MAT, or medication-assisted treatment, is the use of FDA-approved medications combined with counseling and behavioral therapy to treat substance use disorders, primarily opioid and alcohol addiction. It’s considered the gold standard for opioid use disorder treatment, reducing overdose deaths by 38 to 59 percent compared to treatment without medication.
How MAT Works
The core idea behind MAT is that addiction changes brain chemistry, and medication can stabilize those changes while a person works on recovery through therapy and support. SAMHSA describes it as a “whole-patient” approach: the medication handles the biological side of addiction (cravings, withdrawal, the reinforcing high of a substance), and counseling addresses the behavioral and psychological side.
MAT is not a short-term detox program. Many people stay on medication for months, years, or indefinitely, depending on their needs. The goal isn’t necessarily to taper off medication. It’s to keep someone alive, functional, and in recovery.
Medications for Opioid Use Disorder
Three FDA-approved medications are used for opioid addiction, and they work in fundamentally different ways.
Methadone is a full opioid agonist, meaning it activates the same brain receptors that heroin or prescription painkillers do. But it’s dispensed in controlled doses at specialized clinics, so it prevents withdrawal and cravings without producing the intense high of street opioids. It must be taken daily, and most people initially need to visit a clinic in person to receive their dose.
Buprenorphine is a partial opioid agonist. It activates the same receptors, but only partially, and it has a ceiling effect. Once all the receptors are occupied, taking more of the medication produces no additional effect. This makes overdose from buprenorphine alone extremely difficult. It can be prescribed by regular doctors and taken at home, which makes it far more accessible than methadone.
Naltrexone takes the opposite approach. It’s a pure opioid antagonist: it locks onto opioid receptors and blocks them entirely, so if someone uses opioids while on naltrexone, they feel no effect. It doesn’t relieve cravings directly the way buprenorphine or methadone do, and a person must be fully detoxed before starting it, which can be a barrier.
A National Institutes of Health study found that over a 12-month follow-up period, opioid overdose deaths dropped 59 percent among people receiving methadone and 38 percent among those receiving buprenorphine, compared to people not on medication.
Medications for Alcohol Use Disorder
MAT isn’t only for opioid addiction. Three medications are commonly used for alcohol use disorder, each targeting a different piece of the puzzle.
Naltrexone (the same drug used for opioid addiction) blocks the brain’s reward response to alcohol. It reduces the pleasurable, euphoric feeling that reinforces drinking, so even if someone does drink, it feels less rewarding. It’s available as a daily pill or a monthly injection.
Acamprosate works on different brain pathways. It helps normalize the brain’s signaling systems that become disrupted by long-term heavy drinking. The practical effect is reduced cravings and fewer withdrawal-related symptoms, which makes it easier to maintain sobriety after someone has already stopped drinking.
Disulfiram is a deterrent rather than a craving reducer. It blocks the body’s ability to process alcohol properly. If you drink within two weeks of taking it, a toxic byproduct builds up in your blood, causing flushing, headache, nausea, vomiting, and heart palpitations. The unpleasant reaction acts as a powerful motivator not to drink.
The Counseling Component
Medication alone is only half the treatment. MAT programs pair medication with some form of counseling or behavioral therapy. This might include cognitive behavioral therapy (which helps identify and change patterns of thinking that lead to substance use), contingency management (which uses tangible rewards for staying in treatment and remaining abstinent), or group and individual therapy sessions. The specific combination depends on what’s available and what works for the individual.
The counseling piece helps people develop coping strategies, repair relationships, address mental health conditions that often coexist with addiction, and build a sustainable recovery outside of clinical settings. Some treatment programs require regular counseling attendance as a condition of receiving medication, while others are more flexible.
Stigma Around MAT
One of the biggest barriers to MAT is the persistent belief that it simply replaces one addiction with another. This misconception shows up constantly, from family members questioning a loved one’s recovery to social media posts calling medication-based recovery “not real sobriety.” A 2024 study cataloging misinformation about opioid treatment found widespread claims that buprenorphine is more addictive than opioids, that willpower is the only legitimate path to quitting, and that taking medication means a person isn’t truly in recovery.
These beliefs don’t hold up to the evidence. While medications like buprenorphine do create physical dependence (your body adjusts to having the medication), dependence is not the same as addiction. Addiction involves compulsive use despite harm, loss of control, and escalating consequences. Someone stable on buprenorphine who holds a job, maintains relationships, and isn’t chasing a high is in a fundamentally different situation than someone actively using heroin, even though both involve a substance that acts on opioid receptors. The distinction matters because stigma keeps people from starting or staying on treatments that dramatically reduce their risk of dying.
Access and Cost
How you access MAT depends on the medication. Methadone for opioid addiction can only be dispensed through federally certified opioid treatment programs, which means daily or near-daily clinic visits, at least initially. Buprenorphine, by contrast, became much easier to access after Congress eliminated the special waiver (known as the X-waiver) that doctors previously needed to prescribe it. Since 2023, any practitioner with a standard DEA registration and Schedule III prescribing authority can prescribe buprenorphine for opioid use disorder, with no cap on the number of patients they can treat. New DEA registrants do need to complete eight hours of training on substance use disorders.
Cost varies significantly depending on the medication and whether you have insurance. Without insurance, buprenorphine tablets run roughly $106 to $189 per month, while the combination buprenorphine-naloxone film (the most commonly prescribed form) ranges from $112 to $518 per month. Naltrexone tablets cost $25 to $60 monthly, but the injectable form, which only needs to be given once a month, costs $700 to $1,100 per dose.
Insurance coverage has improved substantially. The Affordable Care Act requires most private plans to cover substance use disorder treatment, including medications, with cost-sharing limits comparable to other medical conditions. Medicare covers opioid use disorder treatment through opioid treatment programs and waives cost-sharing for those services. Medicaid programs have been required to cover all FDA-approved medications for opioid use disorder since 2020, with copayments as low as $4 to $8 for people with lower incomes.
What Starting MAT Looks Like
If you’re considering MAT for opioid addiction, the process depends on the medication. For buprenorphine, you’ll typically see a doctor or nurse practitioner who will assess your substance use history, current health, and goals. You usually need to be in early withdrawal before taking your first dose, because starting buprenorphine while opioids are still active in your system can trigger sudden, severe withdrawal. After that, doses are adjusted over the first few days until cravings and withdrawal symptoms are controlled, and you’ll receive a prescription to take at home.
For naltrexone, the process requires a longer runway. You need to be completely free of opioids for 7 to 14 days before starting, because naltrexone will immediately block all opioid receptors and send you into withdrawal if any opioids remain in your system. This detox period is the main reason naltrexone is harder to initiate than buprenorphine, even though the medication itself is effective once started.
For alcohol use disorder, starting medication is generally simpler. Naltrexone and acamprosate don’t require a specific withdrawal timeline the way opioid medications do, though your doctor will want to assess liver function and overall health before prescribing. Disulfiram should only be started after you’ve stopped drinking, since the whole point is to create an aversive reaction if alcohol is consumed.
Regardless of the medication, expect some form of regular check-ins, whether that’s monthly doctor visits, therapy sessions, or drug screening, especially in the early months. The frequency typically decreases as treatment stabilizes.